Patents Assigned to Takeda Pharmaceutical Company Limited
  • Publication number: 20220391921
    Abstract: Described herein are embodiments of an electronic gas emission management system. The system accepts values for a plurality of emission sources of a portfolio according to native input formats for the plurality of emission sources. The system translates the native input formats into a first format, wherein the first format allows comparing emissions among the plurality of emission sources. The system accepts user input specifying a target emission for the portfolio. The system determines values for one or more parameters using the emission values for the plurality of emission sources stored in the first format and generates a display for the portfolio based on the parameter(s).
    Type: Application
    Filed: October 23, 2020
    Publication date: December 8, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Richard Todd Wilner, Jason Leedy, David Shane McCarroll, Sandor Miletic, Nader Ali
  • Publication number: 20220388995
    Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 14, 2021
    Publication date: December 8, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Eiji KIMURA, Masaki OGINO, Yasuhisa KOHARA, Tomoko OHASHI, Tomohiro KAKU, Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO
  • Patent number: 11512066
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • Publication number: 20220370491
    Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 24, 2022
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Testuya Nagata, Hideki Furukawa, Takatoshi Yogo, Yasuo Nakagawa, Shigekazu Sasaki, Ryosuke Tokunoh, Tomohiro Seki, Kosuke Hidaka, Fumiaki Kikuchi, Osamu Kubo, Takahito Kasahara, Takuto Kojima, Junsi Wang, Norihito Tokunaga
  • Patent number: 11505620
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Publication number: 20220365101
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Patent number: 11498898
    Abstract: The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: November 15, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomomi Ikemoto, Hideya Mizufune, Toshiaki Nagata, Takeshi Yamasaki
  • Publication number: 20220356516
    Abstract: The present invention provides an improved quantitative PCR method (qPCR method) for measuring a quantity of a target gene included in a human cell, the method enabling a more accurate analysis of cell kinetics in cell therapy, for example. The qPCR method of the present invention includes a step of adding, to a biological sample including the human cell, a predetermined quantity of exogenous DNA that does not cross over with the target gene as an external standard for correcting a measured quantity of the target gene.
    Type: Application
    Filed: September 29, 2020
    Publication date: November 10, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shinichi MATSUMOTO, Shunsuke YAMAMOTO, Akihiko GOTO, Miyuki FUKUDA, Hideki HIRABAYASHI
  • Patent number: 11492388
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
  • Patent number: 11495331
    Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 8, 2022
    Assignees: TAKEDA PHARMACEUTICAL COMPANY LIMITED, PATCORE, INC.
    Inventors: Hiroshi Nara, Junya Shirai, Tatsuki Koike, Kenjiro Sato, Takaharu Hirayama, Hiromi Fukuda, Tsutomu Morita, Hiromasa Ishihara, Kazue Suzuki, Hiroki Sakamoto, Fumiaki Kikuchi, Kenta Tamaki, Toru Tanoue, Yuichi Horita, Takeshi Ueda
  • Patent number: 11479877
    Abstract: Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: October 25, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
  • Patent number: 11464869
    Abstract: The invention provides, inter alia, methods of treating a disorder characterized by pathological activity of CD30+ cells, such as in certain solid, hematological and lymphoid cancers, in a non-adult human subject by administering an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as, brentuximab vedotin, to the subject. The invention also provides corresponding kits and articles of manufacture suitable for performing the methods provided by the invention.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 11, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Adedigbo Fasanmade
  • Patent number: 11465994
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: October 11, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Martin Teall, Kathryn White, Stephen Mack, Gemma Liwicki, Anne Stephenson, Louise Dickson
  • Publication number: 20220313733
    Abstract: A method for producing renal stromal cells, comprising a step (3) of culturing renal stromal precursors in a medium comprising a platelet derived growth factor receptor agonist to obtain renal stromal cells is provided as a technique for supplying renal stromal cells. This production method can further comprise a step (2) of inducing renal stromal precursors from neural crest cells, and a step (1) of culturing pluripotent stem cells in a medium comprising a GSK3? inhibitor, a TGF? inhibitor, and retinoic acid and/or a derivative thereof to induce neural crest cells.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 6, 2022
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Makoto IKEYA, Daisuke KAMIYA
  • Publication number: 20220315668
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
    Type: Application
    Filed: February 16, 2022
    Publication date: October 6, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Burt Adelman, Yung Chyung, Jennifer Schranz
  • Patent number: 11459325
    Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
  • Patent number: 11458477
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Patent number: 11453661
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: September 27, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
  • Patent number: 11447488
    Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tomoaki Hasui, Shinji Nakamura, Satoshi Mikami, Tohru Yamashita
  • Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman